How to prevent and manage hyperammonemic encephalopathies in valproate therapy

Bibliographic Details
Title: How to prevent and manage hyperammonemic encephalopathies in valproate therapy
Authors: Marleen M M Mitschek, Thomas Vanicek, Jakob Unterholzner, Christoph Kraus, Ana Weidenauer, Angela Naderi-Heiden, Richard Frey, Leo R Silberbauer, Gregor Gryglewski, Konstantinos Papageorgiou, Dietmar Winkler, Markus Dold, Siegfried Kasper, Nicole Praschak-Rieder, Lucie Bartova
Source: Journal of Affective Disorders Reports, Vol 5, Iss , Pp 100186- (2021)
Publisher Information: Elsevier, 2021.
Publication Year: 2021
Subject Terms: Mental healing, RZ400-408
More Details: Background: Valproic acid (VPA) has been increasingly shown to trigger hyperammonemic encephalopathies in patients suffering from urea cycle defects and in those receiving polypharmacy. Methods: We report on two cases of psychiatric inpatients with regular VPA intake who showed severe cognitive impairment due to non-cirrhotic hyperammonaemia without VPA overdosing. Results: In the first case, OTC deficiency appeared to be the underlying cause of a comatose state in a middle-aged bipolar female patient. Besides hyperammonemia, we identified increased plasma levels of glutamine and alanine, decreased plasma levels of arginine and urea, as well as increased urinary levels of orotate. In the second case, we observed severe cognitive impairment in a younger male patient with a current psychotic episode with predominant affective symptoms who we treated with polypharmacy including VPA and topiramate. Limitations: As this case series focused on individual patients, the results should be interpreted with caution and cannot be generalized. Conclusions: In patients receiving VPA, considering urea cycle deficiencies and potential drug interactions seems crucial for avoiding potential life-threatening symptoms.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2666-9153
Relation: http://www.sciencedirect.com/science/article/pii/S266691532100113X; https://doaj.org/toc/2666-9153
DOI: 10.1016/j.jadr.2021.100186
Access URL: https://doaj.org/article/b923c4b70ae840a1b53a9e91fd152650
Accession Number: edsdoj.b923c4b70ae840a1b53a9e91fd152650
Database: Directory of Open Access Journals
More Details
ISSN:26669153
DOI:10.1016/j.jadr.2021.100186
Published in:Journal of Affective Disorders Reports
Language:English